Loading

Please wait...

Kynamro

Generic Name: mipomersen (MYE poe mer sen)
Brand Names: Kynamro
Kynamro (mipomersen) is used together with a low-fat diet to lower total cholesterol in people with homozygous familial hypercholesterolemia. Includes Kynamro side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Kynamro

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Kynamro (mipomersen) is a cholesterol-lowering medication. It reduces blood levels of "bad" cholesterol, such as low-density lipoprotein (LDL), apolipoprotein-B (apo-B), or non-high-density lipoprotein (non-HDL). Kynamro is used together with a low-fat diet and other treatments to lower total cholesterol in people with homozygous familial hypercholesterolemia (an inherited type of high cholesterol). Kynamro is not for use in people with heterozygous familial hypercholesterolemia It is not known whether Kynamro will lower your risk of heart disease. Learn more

Kynamro Side Effects

Kynamro Side Effects

Note: This document contains side effect information about mipomersen. Some of the dosage forms listed on this page may not apply to the brand name Kynamro.

In Summary

Common side effects of Kynamro include: bleeding at injection site, fatigue, flu-like symptoms, hematoma at injection site, increased serum alanine aminotransferase, lipomatosis, rash at injection site, arthralgia, fever, increased serum aspartate aminotransferase, injection site reaction, myalgia, nausea, chills, induration at injection site, inflammation at injection site, skin discoloration at injection site, swelling at injection site, erythema at injection site, malaise, pain at injection site, and tenderness at injection site. Other side effects include: abnormal hepatic function tests, and vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to mipomersen: subcutaneous solution

Warning

Subcutaneous route (Solution)

Mipomersen sodium can cause elevations in transaminases and also increases hepatic fat (with or without concomitant increases in transaminases). Hepatic steatosis is a risk factor for advanced liver disease, including steatohepatitis and cirrhosis. Measure ALT, AST, alkaline phosphatase, and total bilirubin prior to initiation. Measure ALT and AST regularly. If ALT or AST are 3 times the ULN or greater, interrupt therapy. If clinically significant liver toxicity occurs, discontinue therapy. Mipomersen sodium is available only through a restricted program called the Kynamro® REMS. Prescribe mipomersen sodium only to patients with a clinical or laboratory diagnosis consistent with homozygous familial hypercholesterolemia.

Along with its needed effects, mipomersen (the active ingredient contained in Kynamro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking mipomersen:

More common

  • Chills
  • cough
  • dark urine
  • diarrhea
  • fever
  • general feeling of discomfort or illness
  • headache
  • joint pain
  • light-colored stools
  • loss of appetite
  • muscle aches and pains
  • nausea and vomiting
  • runny nose
  • shivering
  • sore throat
  • sweating
  • trouble sleeping
  • unusual tiredness or weakness
  • upper right abdominal or stomach pain
  • vomiting
  • yellow eyes and skin

Less common

  • Arm, back, or jaw pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • chest pain or discomfort
  • chest tightness or heaviness
  • fast or irregular heartbeat
  • irregular, pounding, or racing heartbeat or pulse
  • rapid weight gain
  • shortness of breath
  • sweating
  • tingling of the hands or feet
  • unusual weight gain or loss

Some side effects of mipomersen may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • pain in the arms or legs

Less common

  • Abdominal or stomach pain

For Healthcare Professionals

Applies to mipomersen: subcutaneous solution

Cardiovascular

Common (1% to 10%): Hypertension (7%), angina pectoris (4%), palpitations (3%)

Dermatologic

Very common (10% or more): [All injection site reactions (84%)], erythema (59%), pain (56%), hematoma (32%), pruritus (29%), swelling (18%), discoloration (17%)

Gastrointestinal

Very common (10% or more): Nausea (14%)

Common (1% to 10%): Vomiting (4%), abdominal pain (3%)

Hepatic

Very common (10% or more): Alanine aminotransferase (ALT) increased (10%)

Common (1% to 10%): Hepatic steatosis (7%), aspartate aminotransferase (AST) increased (6%), liver function test abnormal (5%), hepatic enzyme increased (3%)

Immunologic

Rare (less than 0.1%): One case of hypersensitivity with angioedema was reported

Metabolic

Common (1% to 10%): Proteinuria (9%), peripheral edema (5%)

Musculoskeletal

Common (1% to 10%): Pain in extremity (7%), musculoskeletal pain (4%)

Nervous system

Very common (10% or more): Fatigue (15%), headache (12%)

Common (1% to 10%): Pyrexia (8%), chills (6%)

Oncologic

Common (1% to 10%): Neoplasms [benign and malignant] (4%)

Psychiatric

Common (1% to 10%): Insomnia (3%)

Renal

Rare (less than 0.1%): One case of glomerular nephritis was reported

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Kynamro